In vivo antitumor activity and induction of insulin-like growth factor- 1-resistant apoptosis by SC-ααδ9

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 2, 2000, Pages 530-537

  Vogt, Andreas ^a   Wang, Angela S ^a   Johnson, Candace S ^a,c   Fabisiak, James P ^a,b   Wipf, Peter ^b,c   Lazo, John S ^a,b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [BENZYL [2 [(2,5 DIPHENYLOXAZOLE 4 CARBONYL)AMINO]ETHYL]CARBAMOYL] 2 DECANOYLAMINOBUTYRIC ACID; ETOPOSIDE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ENZYME REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

AMINOBUTYRIC ACIDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARBOPLATIN; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG INTERACTIONS; ETOPOSIDE; INHIBITORY CONCENTRATION 50; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-3; MICE; OXAZOLES; RECEPTOR, IGF TYPE 1; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0033971821     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Altschuler D, Yamamoto K and Lapetina EG (1994) Insulin-like growth factor-1-mediated association of p85 phosphatidylinositol 3-kinase with pp 185: Requirement of SH2 domains for in vivo interaction. Mol Endocrinol 8:1139-1146.
2. Baselga J and Mendelsohn J (1994) Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmccol Ther 64:127-154.
3. Baserga R (1993) Gene regulation by IGF-I. Mol Reprod Dev 35:353-356.
4. Baserga R (1995) The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res 55:249-252.
5. Baserga R (1996) Controlling IGF-receptor function: A possible strategy for tumor therapy. Trends Biotechnol 14:150-152.
6. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH and Pollak M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science (Wash DC) 279:563-566.
7. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241.
8. del Peso L, Gonzalez-Garcia M, Page C, Herrera R and Nunez G (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (Wash DC) 278:687-689.
9. Dunn SE, Hardman RA, Kari FW and Barrett JC (1997) Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 57:2687-2693.
10. Fabisiak JP, Kagan VE, Ritov VB, Johnson DE and Lazo JS (1997) Bcl-2 inhibits selective oxidation and externalization of phosphatidylserine during paraquat-induced apoptosis. Am J Physiol 272:C675-C684.
11. Geier A, Beery R, Haimsohn M and Karasik A (1995) Insulin-like growth factor-1 inhibits cell death induced by anticancer drugs in the MCF-7 cells: Involvement of growth factors in drug resistance. Cancer Invest 13:480-486.
12. Harrington EA, Bennett MR, Fanidi A and Evan GI(1994) c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 13:3286-3295.
13. Hayry P, Myllarniemi M, Aavik E, Alatalo S, Aho P, Yilmaz S, Raisanen-Sokolowski A, Cozzone G, Jameson BA and Baserga R (1995) Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat. FASEB J 9:1336-1344.
14. Johnson CS, Chang MJ, Yu WD, Modzelewski RA, Grandis JR, Vlock DR and Furmanski P (1993) Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-hearing C3H/HeJ mice. Cancer Chemother Pharmacol 32:339-346.
15. Jung Y, Miura M and Yuan J (1996) Suppression of interleukin-1 beta-converting enzyme-mediated cell death by insulin-like growth factor. J Biol Chem 271:5112-5117.
16. Kaleko M, Rutter WJ and Miller AD (1990) Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 10:464-473.
17. Kulik G, Klippel A and Weber MJ (1997) Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 17:1595-1606.
18. Kulik G and Weber MJ (1998) Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol 18:6711-6718.
19. Middaugh CR, Mach H, Burke CJ, Volkin DB, Dabora JM, Tsai PK, Bruner MW, Ryan JA and Marfia KE (1992) Nature of the interaction of growth factors with suramin. Biochemistry 31:9016-9024.
20. Myers MG Jr, Zhang Y, Aldaz GA, Grammer T, Glasheen EM, Yenush L, Wang LM, Sun XJ, Blenis J, Pierce JH and White MF (1996) YMXM motifs and signaling by an insulin receptor substrate 1 molecule without tyrosine phosphorylation sites. Mol Cell Biol 16:4147-4155.
21. Norman BH, Shih C, Toth JE, Ray JE, Dodge JA, Johnson DW, Rutherford PG, Schultz RM, Worzalla JF and Vlahos CJ (1996) Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. J Med Chem 39:1106-1111.
22. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP and Korsmeyer SJ (1990) Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144:3602-3610.
23. Parrizas M, Saltiel AR and LeRoith D (1997) Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem 272:154-161.
24. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J and Demaille A (1993) Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29:A492-A497.
25. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D and Baserga R (1993) Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53:1102-1106.
26. Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol. 124:1-6.
27. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, Zoltick P and Baserga R (1995a) The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55:2463-2469.
28. Resnicoff M and Baserga R (1998) The role of the insulin-like growth factor I receptor in transformation and apoptosis. Ann NY Acad Sci 842:76-81.
29. Resnicoff M, Burgaud JL, Rotman HL, Abraham D and Baserga R (1995b) Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res 55:3739-3741.
30. Resnik JL, Reichart DB, Huey K, Webster NJ and Seely BL (1998) Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 58:1159-1164.
31. Rice RL, Rusnak JM, Yokokawa F, Yokokawa S, Messner DJ, Boynton AL, Wipf P and Lazo JS (1997) A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation. Biochemistry 36:15965-15974.
32. Rodriguez-Tarduchy G, Collins MK, Garcia I and Lopez-Rivas A (1992) Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells. J Immunol 149:535-540.
33. Romano G, Prisco M, Zanocco-Marani T, Peruzzi F, Valentinis B and Baserga R (1999) Dissociation between resistance to apoptosis and the transformed phenotype in IGF-I receptor signaling. J Cell Biochem 72:294-310.
34. Sell C, Baserga R and Rubin R (1995) Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 55:303-306.
35. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, Rubin R, Efstratiadis A and Baserga R (1994) Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14:3604-3612.
36. Surmacz E, Nugent P, Pietrzkowski Z and Baserga R (1992) The role of the IGF1 receptor in the regulation of cdc2 mRNA levels in fibroblasts. Exp Cell Res 199: 275-278.
37. Valentinis B, Romano G, Peruzzi F, Morrione A, Frisco M, Soddu S, Cristofanelli B, Sacchi A and Baserga R (1999) Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways. J Biol Chem 274:12423-12430.
38. Vogt A, Rice RL, Settineri CE, Yokokawa F, Yokokawa S, Wipf P and Lazo JS (1998) Disruption of insulin-like growth factor-1 signaling and down-regulation of cdc2 by SC-ααα9, a novel small molecule antisignaling agent identified in a targeted array library. J Pharmacol Exp Ther 287:806-813.
39. Wang LM, Myers MGJ, Sun XJ, Aaronson SA, White M and Pierce JH (1993) IRS-1: Essential for insulin-and IL-4-stimulated mitogenesis in hematopoietic cells. Science (Wash DC) 261:1591-1594.
40. Wipf P, Cunningham A, Rice RL and Lazo JS (1997) Combinatorial synthesis and biological evaluation of library of small-molecule Ser/Thr-protein phosphatase inhibitors. Bioorg Med Chem 5:165-177.
41. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ. Lippman ME and Rosen N (1989) Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer. Mol Endocrinol 3:509-517.